- World Pharma News Home » Clinical Trials » Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November
(a free service delivered by FeedBurner)
The development of Xarelto® (rivaroxaban), a novel oral anticoagulant, has taken another step forward. Phase II results in patients with acute coronary syndrome (ACS) have been chosen for the Late Breaking Clinical Trial session at the American Heart Association's (AHA) upcoming Annual Meeting in New Orleans, USA. The presentation will be held on November 10th, 2008 by C. Michael Gibson, M.D., from Harvard Medical School, Boston, USA.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments